News >

Bevacizumab Benefit Varies Among Ovarian Cancer Subtypes

Jason Harris
Published: Friday, May 19, 2017

Brian Slomovitz, MD

Brian Slomovitz, MD

Patients with proliferative or mesenchymal ovarian tumors treated with bevacizumab (Avastin) had superior progression-free survival (PFS) and a trend toward improved overall survival (OS) compared with patients with immunoreactive or differentiated tumors, according to results published in Clinical Cancer Research.

“It’s an interesting idea. It’s a great idea. In order for us to get better at treating patients with cancer, we need to do a better job identifying different subgroups of patients who will respond to different therapies.”
Kommoss S, Winterhoff B, Oberg AL, et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clin Cancer Res [published online February 3, 2017]. doi:10.1158/1078-0432.CCR-16-2196.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication